Pfizer (NYSE: PFE) is offering a dividend yield of roughly 6% today. That is well above the roughly 1% yield on offer from the S&P 500 index (SNPINDEX: ^GSPC) and the 1.4% average yield of pharmaceutical stocks. There are good reasons for the negative view of Pfizer, but investors may be ignoring the company's over 100-year history of success. Here's why you may want to consider buying this out-of-favor dividend stock while others are fearful.
Pfizer's stock rocketed higher during the coronavirus pandemic, as investors myopically focused on the company's COVID vaccine. When COVID turned out to be a less serious long-term threat than originally believed, Wall Street dumped Pfizer. At this point, the stock is down more than 50% from its 2021 high. That is a big part of the story behind the high yield.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
However, there's another piece that is more fundamental to the pharmaceutical industry. Like all drug makers, Pfizer's drugs receive time-limited patent protections. When patents expire, generic versions of the medications can be produced. That generally leads to a dramatic decline in revenue from Pfizer's drugs. Right now, Pfizer is facing down some notable patent expirations. This is a completely normal dynamic in the pharmaceutical sector.
Patent expirations are why drug companies are always on the lookout for new drugs. The problem is that patent expirations follow a set schedule, but drug development does not. Pfizer's drug pipeline isn't producing major new drugs right now, and it looks like it may have to work through a period in which new drugs won't fully offset revenue lost to patent expirations. This isn't uncommon, either, but investors are likely focusing on the short term rather than the long term when it comes to Pfizer.

#patent #yield #drug #expirations

Doctors discuss COVID, flu and RSV vaccines recommended this year.
As the weather turns colder, it also means respiratory virus season is upon the United States.
In its annual outlook report, the Centers for Disease Control and Prevention (CDC) said it expects the 2026-27 respiratory virus season to have a similar number of peak hospitalizations from influenza, COVID-19 and RSV compared to last season.
Public health specialists told ABC News the best way for people to protect themselves against these viruses is to get vaccinated.
Flu vaccine

#season #virus #centers

Karl-Anthony Towns says the pandemic brought him closer to Jordyn Woods, deepening a friendship that eventually became a marriage.
The New York Knicks center told PEOPLE that having COVID-19 "broke me down to the core," while also helping shape the man he became.
He said Woods witnessed his illness firsthand and understands why he remains particularly protective of himself and his family when it comes to the virus.
The interview comes as Towns serves as a paid spokesperson for Sanofi in a campaign promoting NUVAXOVID, a protein-based COVID-19 vaccine. Sanofi announced the partnership on Oct. 2.
Towns' mother, Jacqueline Cruz-Towns, died on April 13, 2020, at 58 after spending about a month hospitalized with COVID-19. His father, Karl Towns Sr., also contracted the virus and recovered. Other relatives died as the pandemic continued.

#towns #covid #virus #died

M*A*S*H star Alan Alda recently sat down with CBS Sunday Morning's Dr. Jon LaPook, revealing a nightmarish story from his childhood. When the actor was seven, he battled polio, and like tens of thousands of other Americans during the 1950s and 60s, the now-eliminated virus left Alda with serious symptoms at the time.
Alda explained, "I had polio before there was a vaccine. It was pretty hard to experience." He continued, contextualizing the experience, "My father had just gotten a huge part, his first big part, playing George Gershwin in the biopic of Gershwin. And about a week after he started shooting, I got polio." Of course, Alda was referring to Robert Alda, the vaudeville, Broadway, and alter, film star.
And here's where the story takes an even scarier turn. "He and my mother had to administer the treatment, which was almost scalding hot packs of wool on every limb. So they're practically torturing their kid. I remember thinking it was hard on them. There's a little bit of empathy. But I knew it was hard for them." Despite the harsh treatments, Alda was, as he described, "All stiff and I couldn't walk. I was affected in every limb but one arm."
If you're wondering what Carol Burnett has to do with the M*A*S*H star's scalding wool treatment, he shared, "She lived about two blocks away while I was in my house with polio. I would stand on the bed and look out the window and see kids playing, and I was waiting for the time I'd be out there playing with them."
Photo credit: Tammie Arroyo/AFF/SB / MEGA

#star

Keke Palmer isn't interested in the internet's "mom-shaming."
The actress, singer and television host is speaking up about the pressures parents face online, where everything from car seats to kids' diets can bring unwanted criticism, without accounting for the lack of resources or varying challenges some families may face.
As flu and cold season approaches, she spoke with USA TODAY about her partnership with Beyfortus (nirsevimab), a preventive non-vaccine antibody shot for respiratory syncytial virus, or RSV, and how she takes preventative measures to protect the health of her 3-year-old son, Leo.
Respiratory syncytial virus is a common and easily spread virus that peaks during colder months. While most cases are mild, severity is unpredictable. According to the Centers for Disease Control and Prevention, 2% to 3% of infants under 6 months are hospitalized with RSV every year.
Palmer also opened up about motherhood, modeling healthy habits for her son and why she believes parents should have these open conversations without judging one another's choices.

#face

A 40-year-old Pennsylvania woman who died with what appears to be measles-related complications also had ongoing lung problems, including asthma and COPD, according to the coroner's office who handled the case. It would be the third measles-related death in Pennsylvania amid a surging outbreak of the virus. 693 cases had been confirmed so far this year in the state, with 99 in the last week alone. NBC News' Erika Edwards reports.

#erika

Kansas City, Missouri — Vice President JD Vance announced Monday the Trump administration will suspend roughly 870,000 people suspected of defrauding pandemic-era small business programs from receiving future federal loans.
The vice president contended that borrowers who stole taxpayer money should no longer be eligible to receive loans from government-backed programs.
"If you screwed the American taxpayer, the federal government is now going to say you're cut off, no more," Vance told reporters. "You shouldn't be applying anymore, and if you do apply, you're no longer able to get those benefits."
His remarks came as the Justice Department announced a slew of cases in a nationwide crackdown on fraud involving the COVID-19-era Paycheck Protection Program.
The department's enforcement push, which ran from June 12 through Sept. 1 and was dubbed "Heartland fraud surge," resulted in actions involving more than 160 defendants and approximately $245 million in intended losses to taxpayers. The operation was put into action more than five years after the government pushed emergency loans to businesses nationwide that were struggling as a result of the coronavirus pandemic.

#president #pandemic #federal

KINSHASA, Congo (AP) — The Ebola outbreak in eastern Congo, the world's fastest-growing outbreak of the disease on record, has now spread to seven provinces in the African country, local authorities said. And it's showing no signs of slowing down.
According to the governor of the northwestern province of Sud-Ubangi, Jean-Rene Galekwa Vundawe, laboratory tests by Congo's national research institute found in a sample the Bundibugyo virus, the rare kind of Ebola that caused the current outbreak.
The statement, which was issued on Thursday and reported by local media outlets on Friday, said the sample was from the Bulu health district in Sud-Ubangi. It did not disclose other information about the source of the infection.
The development makes Sud-Ubangi the seventh province affected by the outbreak — and the first in western Congo — a worrisome spread west from what was previously concentrated in the country's east. A case was detected in Kinshasa in May in a person who had traveled from eastern Congo, but the Congolese capital was not classified as an affected province.
As of Wednesday, 6,942 cases and 3,349 deaths have been reported, according to the latest government figures.

#outbreak #local

Two wins in the Bundesliga, one in the cup, one in the UEFA Champions League – BVB have recently celebrated four consecutive victories. In the Bundesliga table, the Black and Yellows sit in third place with the maximum return of six points. Speaking about the clash against Villarreal FC (3:2) in midweek, BVB coach Niko Kovac said: "Of course, you expend a lot physically, but also mentally. Now it's about getting the mental side back under control immediately in order to switch back to the Bundesliga." His team are the favorites against the newly promoted side: "We're playing at home and we want to win, that's our goal." But: "There are no easy games in the Bundesliga. You have to approach them in a way that means you're fully there right away. That's why I want my boys to step on the gas from the first minute and get our fans behind us again as quickly as possible so that we can play successful football."
Nico Schlotterbeck and Ramy Bensebaini have returned to team training after their injuries and are available for the Paderborn match. "They are fit, healthy and ready to play this weekend. I can count on both of them," said Kovac. Konstantinos Karetsas will not be involved after having to be substituted in the game against Villarreal FC due to circulation problems. Read more now!
SC Paderborn have been promoted to the Bundesliga for the third time in the club's history. "A team with the ambition to stay in the league. We will certainly be facing a deep block from the opposition, who will want to hit on the counter," said Kovac. On matchday one, the team picked up a point away at FSV Mainz 05 (0:0) and then lost 1:0 at home to SC Freiburg. They currently sit 12th in the table. Despite 23 shots on goal, Paderborn have yet to score. Defensively, however, they have not allowed much either and have goalkeeper Nahuel Noll to thank, as he has conceded only one goal so far. Paderborn's Felix Götze (in the BVB youth setup until 2014) and Steffen Tigges (2019 to 2022) also wore the Black and Yellow shirt in the past.
BVB have never lost a competitive match against SC Paderborn: there have been two meetings in the DFB-Pokal, and on both occasions the Black and Yellows advanced to the next round. In the Bundesliga, Borussia have won two matches so far, while two others ended in draws. The last Bundesliga meeting at the end of May 2020 is especially memorable. In this ghost game in Paderborn played behind closed doors due to the coronavirus, the Black and Yellows produced a poor first half but improved after the break. All seven goals in the 6:1 victory came in the second half. It was the highest-scoring half of the 2019/20 season. For BVB, Jadon Sancho (3), Thorgan Hazard, Achraf Hakimi and Marcel Schmelzer, with the last goal of his professional career, were on target.Christina Reinke
This article was translated into English by Artificial Intelligence. You can read the original version in 🇩🇪 here.

#yellows #goal #half

CVS Health (NYSE: CVS) dealt with significant headwinds after the COVID-19 pandemic. The company's financial results suffered as sales of coronavirus-related products (such as diagnostic tests) declined, while expenses in its insurance business rose substantially, resulting in lower profits and margins. However, CVS Health has done a good job of addressing those problems, and the stock has rebounded. Shares are up 31% over the past 12 months. Wall Street thinks there may be even more upside on the horizon. CVS Health's average price target is $116.04 (according to Yahoo! Finance), implying a meaningful 20% upside from current levels. Is now a great time to buy the stock?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Over the past 18 months (or so), CVS Health has implemented several initiatives that have helped improve its business. For instance, the company closed dozens of stores, many of which were unprofitable. The pharmacy chain specialist also scaled back its insurance division, notably by exiting the Affordable Care Act marketplace. The results have been pretty impressive. Consider the company's second-quarter results. CVS Health's revenue increased by a healthy 7.3% year over year to $106.1 billion.
Adjusted earnings per share were $2.58, 42.5% higher than the year-ago period. Note the improvement in CVS Health's healthcare benefits segment, which offers health insurance services. Operating expenses as a percentage of revenue declined slightly to 12.4%, down from 12.5% in the prior-year quarter, even as revenue grew 3.5% year over year. And operating margins within this unit came in at 5.8%, up from the 2.8% reported in the year-ago period. Also, CVS Health's medical benefits ratio -- the percentage of insurance premiums the company spent on medical care (the lower the better) -- declined to 87.4% in the second quarter, down from 89.9% in Q2 2025.
CVS Health also increased its guidance for the full fiscal year 2026. The company now expects its adjusted EPS to fall between $7.90 and $8.10, up from its previous range of between $7.30 to $7.50. The company is also now projecting cash flow from operations of at least $11.5 billion, up from the previous lower bound of $9.5 billion. These are signs of a much-improved business.

#insurance

Pamela Anderson says a doctor told her she probably had only 10 years to live after she was diagnosed with hepatitis C, leaving her terrified about what would happen to her two young sons.
Anderson revisited the diagnosis while accepting amfAR's Award of Courage at the organization's Sept. 6 gala in Venice. She described hepatitis C as a "death sentence" at the time because the treatments then available had not given her the certainty that later antiviral drugs would provide.
She ultimately completed a 12-week antiviral treatment and announced in 2015 that she was free of the virus. During her Venice speech, however, Anderson said the years surrounding the diagnosis affected her decisions and left behind feelings of shame and guilt that did not disappear with the medical result.
The 59-year-old actress ended her remarks by rejecting the victim label attached to difficult periods in her life. "I'm not a victim, I'm a victor," she told the audience. "I'm not the damsel in distress, no matter how easy that role is to play."
Anderson publicly disclosed in 2002 that she had hepatitis C. Looking back on that period at the amfAR Gala Venezia, she said the prognosis she received was stark.

#gala #told #years

Pamela Anderson has recalled being given "a death sentence" when she was diagnosed with hepatitis C in the late '90s.
The Baywatch actress gave a powerful speech about her diagnosis and recovery from the virus as she was honoured with amfAR's Award of Courage during the Venice Film Festival on Sunday night.
"It was a death sentence. That's what my doctor told me - that I probably had around 10 years to live," the 59-year-old told the audience, according to Variety. "I'm sure that coloured and corrupted my decisions. It was not fear of death, but fear of what might happen to my young children. It turned my life inside out."
A cure for the viral infection was found in 2011, and Anderson became "hep C free" in 2015 after paying "everything I had in my bank" to receive treatment.
"But my experience of shame and guilt was also an unconscious journey. It stays with me; it haunts me," she continued. "And just like the ******* ual abuse that I endured as a child, it felt like it was carved into my forehead: Damaged goods. And I presented myself as such."
The Last Showgirl star admitted that she has "finally come to terms" with her health news and is using that to fuel her career renaissance.

#death #like #pamela

On August 5, OraSure Technologies (NASDAQ:OSUR) reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier. Revenue of $30.6 million beat the company's own guidance range and climbed 9.7% from the prior quarter. But look past the top line and the story splits in two, one part driven by real operating progress, the other by an accounting adjustment tied to a regulatory setback.
Some of this quarter's improvement came from actual operations. Gross margin expanded to 43.5% on a GAAP basis, up from 42.1% a year earlier, and non-GAAP gross margin rose to 44.2% from 43.2%. Diagnostics revenue grew 1% year over year to $19.4 million, helped by higher syphilis test sales and the addition of BioMedomics' Sickle SCAN product line. OraSure also picked up two regulatory wins during the quarter. In June 2026, the FDA cleared its Colli-Pee Dx urine collection kit for use with Roche's **** ually transmitted infection tests, letting patients collect samples at home instead of in a clinic.
The following month, the FDA granted Emergency Use Authorization for the second-generation OraQuick Ebola 2.0 Rapid Antigen Test, which can detect all four Ebola virus strains known to cause disease in humans. Cash used in operating activities improved to $23.8 million over the first six months of 2026, down from $30 million a year earlier, a sign the cash burn is easing. The company also kept buying back stock, repurchasing $22 million of shares, or 7.7 million shares, against its $40 million authorization, retiring more than 10% of shares outstanding.
The GAAP profit that headlines this quarter didn't come from the business getting more profitable. It came almost entirely from a $22.6 million reduction in a contingent consideration liability, an accounting entry triggered when OraSure updated its regulatory submission plan for the CT/NG test on its Sherlock platform. Strip that adjustment out and the underlying trend looks different. Non-GAAP operating loss widened to $14.7 million from $13.2 million a year earlier, and non-GAAP net loss came in at $13.8 million, roughly in line with last year's $14.2 million loss. The regulatory event behind that accounting gain is itself a setback.
In July, OraSure withdrew its InteliQuick CT/NG molecular self-test submission after receiving FDA feedback, meaning the product's path to market is now delayed while the company prepares a future resubmission. Total revenue for the quarter was still down 2% year over year, and core revenue, which excludes COVID-19 and Risk **** sment Testing, was flat. Six-month revenue fell 4% to $58.6 million. Sample Management Solutions revenue stayed flat year over year at $9.9 million, showing no growth driver of its own. Cash and equivalents fell to $161 million at quarter-end from $199.3 million at the end of 2025, pulled down by continued buybacks and cash used in operations.

#year #gaap #reven

Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying off.
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.

#gilead #NVIDIA #three

Pfizer (NYSE: PFE) has faced several issues in recent years that have weighed on its share price. First, the company's coronavirus business isn't nearly as strong as it once was. Second, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant. Third, the pharmaceutical giant has faced clinical setbacks with otherwise promising pipeline candidates, including some it acquired. This problem has led to billions in impairment charges. Because of these headwinds (and others), Pfizer's shares have lagged broader equities over the past two years and have hovered below $30 apiece. Is it finally time to invest in the company? Let's see whether there is a rebound on the horizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's start with Pfizer's recent second-quarter update. The company's revenue increased by 1% year over year to $15 billion. While that top-line growth doesn't look impressive, it beat ***** yst estimates. On the bottom line, Pfizer's adjusted earnings per share were $0.77, slightly lower than the $0.78 reported in the prior-year quarter. Here too, Pfizer beat expectations. And it's important to highlight what drove the revenue and earnings beat.
The company noted that non-COVID revenue increased 5% year over year, while sales from launched and acquired products jumped 18%. This is great news for Pfizer. It suggests that newer (and acquired) products will help pull sales in the right direction over the medium term, while older medicines, especially within its coronavirus business, continue to lose steam.
Even with the progress Pfizer is making with relatively new launches, upcoming patent cliffs will be a major problem for the company. Consider, for instance, that Eliquis was the drugmaker's best-selling therapy during the second quarter. Pfizer's revenue from Eliquis came in at $2.4 billion, up 21% year over year. So, it arguably remains its single most important growth driver. Pfizer will have to launch more new drugs to fill the gap Eliquis will leave behind as it faces generic competition by the end of the decade. Can the company pull it off? My view is that it can.

#company #revenue #years

Leading U.S. medical groups are urging people to get updated flu and COVID-19 vaccinations this fall, banding together Wednesday to issue shot guidelines — and highlight the science behind them — saying they hope to ease confusion caused by the Trump administration's changing advice.
Flu vaccinations are beginning and COVID-19 shots are starting to arrive after the Food and Drug Administration approved this year's updated versions last week. Winter also brings another vaccine-preventable risk called RSV. Exactly who should get one or all of these vaccines, and when?
That advice usually comes from the Centers for Disease Control and Prevention, with help from its independent advisers. But despite no new scientific evidence, Trump health officials last year began pulling back on some longstanding recommendations for fall virus protection and routine children's vaccinations. And that advisory panel, which influences state and insurance vaccine policies, is caught in a court battle. The CDC didn't respond to questions about any new fall guidance but suggested on its website that doctors follow last year's flu recommendations.
Doctors' groups are filling the gap: the American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America each released vaccination guidelines for their patient populations.
"There's been a lot of confusion and chaos regarding vaccine recommendations," said Dr. Sandra Fryhofer, of the American Medical **** ociation.

#vaccinations #medical

By Mike Sheikh
Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss this unique opportunity.
COCP is not a company that lacks science or researchers. It has a drug discovery platform technology capable of delivering broad spectrum antivirals on demand for high value diseases that include norovirus, influenza, coronaviruses, and hepatitis C. If you had to point to something they were lacking then the missing "it factor" was a clear strategic vision. They needed an operator and a commercialization guru capable of aligning the board to his vision and raising the capital they needed on favorable terms to turn a platform technology into an enterprise.
The appointment of James Sapirstein was a transformative moment for the company.
Sapirstein is a high powered biotech exec with an impeccable pedigree. He's not an eager early-career operator looking to make a name for himself. Investors need to realize he joined after decades of experience in commercial pharmaceutical leadership, antiviral development, product launches, and business development. From his bio we learned that he has participated in or led 23 product launches and has driven numerous business-development transactions. His résumé includes founding CEO of Tobira Therapeutics, CEO of Contravir Pharmaceuticals (Hepion Pharmaceuticals, Inc. NASDAQ: HEPA), executive leadership at Serono Laboratories, senior commercial roles at Gilead Sciences (NASDAQ: GILD), and international marketing leadership in Bristol Myers Squibb's (NYSE:BMY) infectious-disease division.

#NASDAQ #Biotech

ATLANTA (AP) — Georgia prison officials plan to execute a man next month who was convicted of fatally shooting two real estate agents in Atlanta's suburbs more than two decades ago.
Stacey Humphreys, 53, was convicted of malice murder in the 2003 killings of 33-year-old Cyndi Williams and 21-year-old Lori Brown. He is set to receive a lethal injection at the state prison near Jackson at 7 p.m. on Sept. 16, according to the Department of Corrections.
Humphreys would be the first person executed in Georgia this year. The death penalty in the state has largely been tied up in litigation over an agreement related to the coronavirus pandemic that defense lawyers contend temporarily shields many death row residents from execution. The last execution in the state was in March 2024.
Humphreys was previously scheduled to die last December, but the execution was halted after his lawyers filed a petition asking a judge to order two members of the State Board of Pardons and Paroles to recuse themselves from hearing his clemency petition. Humphreys' lawyers argued that the two parole board members had conflicts of interest because they had played roles during his trial.
Kimberly McCoy, one of the board members, was a victim advocate with the Cobb County district attorney's office at the time of Humphreys' trial and was ****** igned to work with the victims in the case. The other, Wayne Bennett, was the sheriff in Glynn County, where the trial was moved because of pretrial publicity, and Humphreys' lawyers argued he oversaw security for the jurors and Humphreys himself during the case.

#year #execution

When the world needed her, Dolly Parton was known to appear — even in the middle of a once-in-a-lifetime global pandemic.
The queen of country left millions mourning after her death on Aug. 25 at the age of 80. Beyond the big hair and chart-topping hits, Parton was known as a prolific philanthropist who poured millions into causes ranging from childhood literacy and leukemia to disaster relief and the preservation of bald eagles.
One of Parton's most notable contributions to medicine was her funding and staunch support of the COVID-19 vaccine, which she publicly pledged to help fund as early as April 2020.
While the scientific and medical communities raced to develop technology to fight the novel virus that was killing thousands, Parton was loud and proud, encouraging the public to trust the process — even during a time when political messaging, misinformation and uncertainty left many unsure where to turn and who to trust.
The mRNA vaccine technology she helped fund has since shown promise in treating and preventing diseases beyond COVID-19, including cancer.

#parton

Novak Djokovic has reignited the COVID-19 vaccine debate after offering a blunt explanation for his decision not to get vaccinated, despite previously testing positive for the virus.
The 24-time Grand Slam champion refused to take the vaccine, a decision that led to his deportation from Australia in 2022 and the cancellation of his visa. At the time, Djokovic said he was not against vaccination but wanted to exercise his right to decide what he put into his body.
The decision resulted in him missing several high-profile tournaments, including the Australian Open and US Open in 2022, Indian Wells in 2022 and 2023, the Miami Open in 2022 and 2023, the Canadian Open in 2022 and the Cincinnati Masters in 2022.
Now, Djokovic has revisited the controversy in the Amazon Prime documentary Novak Djokovic: The Wolf in Winter, explaining why he decided against getting vaccinated despite having previously contracted COVID-19.
Photo by Emilee Chinn/Getty Images

#previously

By Christy Santhosh and Shashwat Chauhan
Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer ‌therapy developed with Merck sent investors piling into the stock.
The therapy is central to Moderna's ‌efforts to prove that its mRNA technology can succeed beyond its COVID-19 vaccine franchise and infectious disease shots, as it seeks to build a more durable revenue base. The company recently added a flu vaccine to its portfolio and is advancing experimental vaccines for conditions including norovirus and Lyme disease.
Analysts had noted the cancer vaccine data could be an important catalyst for the company and potentially strengthen investor sentiment.
"A successful trial gives investors stronger evidence that mRNA technology can ‌have a meaningful future beyond infectious diseases," ⁠said Lale Akoner, global market strategist for eToro.

#market #cancer #Therapy #investors

(NEXSTAR) – Don't be surprised if you start hearing some more coughing in the next few weeks. COVID-19 is once again on the rise in nearly every corner of the U.S.
According to modeling done by the Centers for Disease Control and Prevention, "COVID-19 infections are growing or likely growing in 50 states." No states are seeing cases decline, as of mid-August.
Despite the trend, the CDC says severe cases are still pretty rare. Emergency department visits related to COVID are "very low."
Epidemic trend tracking by the CDC shows COVID 'growing' or 'likely growing' in every state. No estimate was given for Iowa. (Map: CDC)
Wastewater data can give us a closer look at where the virus may be circulating most. Testing the sewage can pick up the presence of COVID-19 in a community and "can pick up signs of infection even from people who feel perfectly healthy," the CDC says.

#growing #every #states #don 't

GREENBELT, Md. (AP) — A former senior adviser to infectious disease expert Dr. Anthony Fauci pleaded guilty Tuesday to plotting to conceal federal records related to research on the origins of the deadly COVID-19 pandemic.
Dr. David Morens is scheduled to be sentenced Nov. 12 by U.S. District Judge Paula Xinis in Greenbelt, Maryland. Morens pleaded guilty to conspiring to defraud the U.S. government, a felony punishable by a maximum prison sentence of five years.
"By pleading guilty today, Dr. Morens has taken responsibility for what he did, and he will continue to do so," defense attorney Tim Belevetz said in a statement after the plea hearing.
Morens is accused of using his private email account to intentionally circumvent public records laws while employed at the National Institute of Allergy and Infectious Diseases. The Justice Department alleges that he concealed or destroyed records of discussions related to COVID-19 research grants, including an effort to revive a controversial coronavirus grant.
The indictment follows a probe by House Republicans into the origins of the COVID-19 pandemic that scrutinized Morens' email communications and accused him of intentionally concealing records. In congressional testimony, Morens denied attempting to evade federal transparency laws by using his personal email.

#records #guilty #infectious #pleaded

The U.S. subsidiary of France-based contract logistics provider ID Logistics Group SA has agreed to pay $2.36 million to resolve allegations that it improperly obtained a Paycheck Protection Program loan from the U.S. Small Business Administration during the Covid crisis for which it was not eligible.
ID Logistics US submitted an application for a PPP loan certifying that, together with its affiliates, it had fewer than 500 employees when it actually had more than 500 employees and, therefore, was not eligible for the loan, the U.S. Attorney's Office for the Middle District of Pennsylvania, announced on Tuesday.
The Coronavirus Aid, Relief and Economic Security (CARES) Act in 2020 provided forgivable loans to small businesses for job retention and other expenses through the Paycheck Protection Program. PPP loans were guaranteed by the SBA and, if the loan proceeds were used for eligible expenses, the SBA would forgive the loan balance and accrued interest.
To obtain a PPP loan, a qualifying business had to submit a PPP loan application to an authorized lender. Whether an applicant qualified as a small business was determined, in part, by ******* sing the number of employees of the business, including any domestic and foreign affiliates.
The fraudulent loan application was flagged for authorities by a whistleblower, who will receive $236,200 from the settlement, according to the Department of Justice.

#business #small #eligible

Fortinet (FTNT) demonstrates strong momentum, with a 98% gain over the past year.
FTNT is projected to grow revenue 19.41% this year and 10.97% next year, with earnings expected to rise 25.02% and 8.95%, respectively.
Analyst sentiment is broadly positive with price targets ranging from $102 to $220.
Technical indicators and investor sentiment suggest FTNT still has room to run, supported by robust fundamentals and moderate short interest.
Valued at $117 billion, Fortinet (FTNT) is a provider of network security appliances and Unified Threat Management network security solutions to enterprises, service providers, and government entities worldwide. Its solutions are designed to integrate multiple levels of security protection, including firewall, virtual private networking (VPN), antivirus, intrusion prevention, web filtering, anti-spam and wide area network acceleration.

#sentiment #solutions #analyst #valued

DAKAR, Aug 14 (Reuters) - The Ebola outbreak in Democratic Republic of ‌Congo has spread to a ‌sixth province, Bas-Uele, located in the northeast of the country, the communications ministry said on Friday, officially confirming a case discovered earlier.
Health authorities have identified a ‌person who ⁠has died from Ebola in the provincial capital Buta, an ⁠official from the National Institute for Biomedical Research told Reuters on Thursday.
Bas-Uele wasn't previously affected by the virus. The ‌new case raised fears that people who have been in contact with the patient may have also been infected.
Delayed detection, conflict and strained health ‌services have helped the virus spread more rapidly than in previous outbreaks.
The latest report, ‌published on the ministry's X account, said that the number of confirmed Ebola cases in Congo has increased to ‌4,665, including 2,184 deaths.

#case

As the death toll from the latest Ebola outbreak in the Democratic Republic of Congo (DRC) surpasses 2,000 people, infectious disease experts say Americans should remain aware of the humanitarian crisis overseas while understanding the reality of domestic risk.
The virus has spread rapidly across parts of eastern and northeastern DRC, with earlier cross-border cases in Uganda. Published government data shows a total of 4,381 confirmed cases.
"There's a lot of people who live there. So this is not breaking out in a town of 50, but in rural cities of hundreds of thousands," David Wohl, M.D., a professor of medicine in the Division of Infectious Diseases at the University of North Carolina at Chapel Hill, told Fox News Digital.
Fauci Texts Suggest Officials Were 'Too Slow To Pivot' Amid Pandemic, Says Dr Marc Siegel
"Compared to previous outbreaks, the pace at which this is moving is unprecedented," he went on.

#infectious #ebola #congo

DAKAR, Aug 11 (Reuters) - The ongoing Ebola outbreak in Democratic Republic of Congo concerns a previously unseen ‌variant of the rare Bundibugyo species of the virus, ‌indicating it stemmed from a new transmission from animals to humans rather than from variants linked to earlier outbreaks, a new study said.
• Researchers from Congo, Uganda, Belgium and other countries ******* ysed the genetic make-up of virus samples from 22 patients in Congo ‌and Uganda and ⁠found the outbreak strain was genetically distinct from previous Bundibugyo Ebola viruses seen in outbreaks in ⁠2007 and 2012.
• The findings, published on Monday in the journal Nature Medicine, suggest the outbreak began with a fresh animal-to-human transmission event and was then spread between people.
• The study did ‌not identify the animal source of the outbreak, but Ebola viruses are known to spill over periodically from infected animals to humans.
• The genetic ******* ysis helped confirm that cases detected in Uganda were linked to the outbreak in Congo.

#congo #virus #animals #humans

Newly released text messages from Dr. Anthony Fauci have sparked fresh questions about his handling of evolving COVID-19 evidence, according to Dr. Marc Siegel, Fox News senior medical ****** yst.
The texts are part of an initial batch of communications from Fauci's government-issued cellphone released Monday by Sens. Ron Johnson, R-Wis., and Rand Paul, R-Ky. The messages shed light on private discussions between Fauci and other top health officials as they navigated evolving questions around the coronavirus pandemic.
In a Monday evening interview, Siegel suggested the former White House chief medical adviser was at times too "dogmatic" and slow to adapt as the science evolved.
Exposed Fauci Diary Shows He Estimated Covid-19 Death Rate To Be Much Lower Than What He Told Congress
Siegel said Fauci was a "top immunologist" and "top vaccinologist."

#siegel #questions

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) said on August 3 that a North Korea-linked adversary injected a malicious dependency into at least 131 Mastra AI framework packages on npm (Node Package Manager). Microsoft Corporation (NASDAQ:MSFT) owns GitHub, which acquired npm in 2020 and operates the registry at the center of the attack chain.
This was a developer-supply-chain breach with unusually efficient distribution. Stolen maintainer credentials let the attacker publish poisoned Mastra versions tagged as the latest releases. The malicious easy-day-js dependency then ran during installation, exposing developer machines and build pipelines to credential theft and remote code execution. CrowdStrike found that 87% of identified software-registry threats in the first half of 2026 involved npm packages.
Image by Tawanda Razika from Pixabay
Microsoft's role cuts both ways. GitHub controls the registry infrastructure, and its advisory database powers npm audit, so repeated account takeovers increase the burden to harden publishing and dependency scanning. Yet Microsoft's own June 17 investigation identified more than 140 affected Mastra packages and detailed detections across Defender Antivirus, Defender for Endpoint and Defender XDR. The same incident that creates reputational risk for npm also gives Microsoft another reason to sell integrated security.
The more direct demand read-through belongs to CrowdStrike. Its fiscal Q1 2027 revenue grew 26% to $1.39 billion, while annual recurring revenue rose 24% to $5.51 billion. Hedge-fund ownership also increased to 79 portfolios at the end of Q1 2026 from 67 in Q4 2025, according to Insider Monkey's database. The valuation is the restraint: a roughly $190 billion market value equals about 32 times CrowdStrike's $5.91 billion to $5.96 billion fiscal-year revenue guidance. The business must sustain growth near the mid-20% range for that multiple to remain comfortable.

#NASDAQ